These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19277123)

  • 1. A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation.
    Aviezer D; Brill-Almon E; Shaaltiel Y; Hashmueli S; Bartfeld D; Mizrachi S; Liberman Y; Freeman A; Zimran A; Galun E
    PLoS One; 2009; 4(3):e4792. PubMed ID: 19277123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system.
    Shaaltiel Y; Bartfeld D; Hashmueli S; Baum G; Brill-Almon E; Galili G; Dym O; Boldin-Adamsky SA; Silman I; Sussman JL; Futerman AH; Aviezer D
    Plant Biotechnol J; 2007 Sep; 5(5):579-90. PubMed ID: 17524049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease.
    Shaaltiel Y; Gingis-Velitski S; Tzaban S; Fiks N; Tekoah Y; Aviezer D
    Plant Biotechnol J; 2015 Oct; 13(8):1033-40. PubMed ID: 25828481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease.
    Abbas R; Park G; Damle B; Chertkoff R; Alon S
    PLoS One; 2015; 10(6):e0128986. PubMed ID: 26053270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.
    Berger J; Vigan M; Pereira B; Nguyen TT; Froissart R; Belmatoug N; Dalbiès F; Masseau A; Rose C; Serratrice C; Pers YM; Bertchansky I; Camou F; Bengherbia M; Bourgne C; Caillaud C; Pettazzoni M; Berrahal A; Stirnemann J; Mentré F; Berger MG
    Clin Pharmacokinet; 2019 Apr; 58(4):469-482. PubMed ID: 30128966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
    Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy for Gaucher disease.
    Charrow J
    Expert Opin Biol Ther; 2009 Jan; 9(1):121-31. PubMed ID: 19063698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology.
    Grabowski GA; Golembo M; Shaaltiel Y
    Mol Genet Metab; 2014 May; 112(1):1-8. PubMed ID: 24630271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
    Kishnani PS; DiRocco M; Kaplan P; Mehta A; Pastores GM; Smith SE; Puga AC; Lemay RM; Weinreb NJ
    Mol Genet Metab; 2009 Apr; 96(4):164-70. PubMed ID: 19195916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term international safety experience of imiglucerase therapy for Gaucher disease.
    Starzyk K; Richards S; Yee J; Smith SE; Kingma W
    Mol Genet Metab; 2007 Feb; 90(2):157-63. PubMed ID: 17079176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability.
    Pastores GM; Rosenbloom B; Weinreb N; Goker-Alpan O; Grabowski G; Cohn GM; Zahrieh D
    Genet Med; 2014 May; 16(5):359-66. PubMed ID: 24263462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, open-label, phase III study of Abcertin in Gaucher disease.
    Lee BH; Abdalla AF; Choi JH; Beshlawy AE; Kim GH; Heo SH; Megahed AMH; Elsayed MAL; Barakat TEM; Eid KMAE; El-Tagui MH; Mahmoud MMH; Fateen E; Park JY; Yoo HW
    Medicine (Baltimore); 2017 Nov; 96(45):e8492. PubMed ID: 29137040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.
    Zimran A; Brill-Almon E; Chertkoff R; Petakov M; Blanco-Favela F; Muñoz ET; Solorio-Meza SE; Amato D; Duran G; Giona F; Heitner R; Rosenbaum H; Giraldo P; Mehta A; Park G; Phillips M; Elstein D; Altarescu G; Szleifer M; Hashmueli S; Aviezer D
    Blood; 2011 Nov; 118(22):5767-73. PubMed ID: 21900191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Velaglucerase alfa: a new option for Gaucher disease treatment.
    Zimran A
    Drugs Today (Barc); 2011 Jul; 47(7):515-29. PubMed ID: 22013559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme replacement therapy in Gaucher's disease: a rapid, high-yield method for purification of glucocerebrosidase.
    Dale GL; Beutler E
    Proc Natl Acad Sci U S A; 1976 Dec; 73(12):4672-4. PubMed ID: 1070017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation analysis of the acid beta-glucosidase gene in a patient with type 3 Gaucher disease and neutralizing antibody to alglucerase.
    Germain DP; Kaneski CR; Brady RO
    Mutat Res; 2001 Nov; 483(1-2):89-94. PubMed ID: 11600137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.